Is It Too Late To Buy November’s Winners, AstraZeneca plc And Vodafone Group plc?

AstraZeneca plc (LON: AZN) and Vodafone Group plc (LON: VOD) have been on a winning streak, Harvey Jones asks whether it can continue

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

November can be a gloomy month but you’ll be happy if you hold shares in AstraZeneca (LSE: AZN) (NYSE: AZN.US) and Vodafone Group (LSE: VOD) (NYSE: VOD.US).

These two FTSE 100 giants have been real winter warmers, their shares up 9% and 16% respectively over the last month.

So can the party continue, or is the hangover is about to kick in?

Wisdom Of AstraZeneca

AstraZeneca’s strong run followed impressive Q3 results, which saw group revenue rise 5% to $6.54bn. Emerging markets led the way, with 12% sales growth, and a storming 22% in China.

Management has an ambitious long-term plan, targeting strong and consistent revenue growth from 2017, with revenues topping $45bn by 2023.

Just 18 months ago, I reckoned the only compelling reason to buy AstraZeneca was its yield, nudging 6% at the time. It was battling against expiring patents and a failing drugs pipeline, while revenues were plunging as it lost exclusive rights to key treatments. Management was shedding staff to make the figures look better.

It’s a different story today. AstraZeneca now has 121 projects in its pipeline, with 107 in the clinical phase of development. Its share price has recovered nicely since Pfizer’s bid was kicked back, and if you like buying on takeover speculation, Pfizer may give it another go.

There are threats, as cuts in government spending could hit drug sales, while earnings per share have been falling, as AstraZeneca pours money into new blockbuster drugs.

But at a reasonable 14.1 times earnings and yielding 3.8%, AstraZeneca is more than a November wonder.

Vodafone Rings In

Vodafone’s recent results also helped fend off the winter blues, despite a 10% drop in half-year earnings to £5.9bn.

Investors were cheered by its full-year guidance, which predicted a slight rise in profits to between £11.4bn and £11.9bn.

Data services continue to rise strongly, with a 59% rise in European 4G coverage, and 10.5 million 4G customers across the group. There is plenty of scope for future growth, as its networks roll out across India.

But it is competing in a tough market, especially in stricken Europe, where half-year service revenues fell 6.5%.

Despite its blistering November, the Vodafone share price is down 2% over the past 12 months. I reckon its future share price growth prospects are limited, as they have been for years.

But its meaty dividend, which currently yields 4.9%, remains almost impossible to resist.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Harvey Jones has no position in any shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »